Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Telix Pharmaceuticals Limited

< Previous 1 2 Next >
Telix Partners with Subtle Medical on AI-Enabled SubtlePET™ Software for Faster PET Imaging with Illuccix®
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
FDA Accepts New Drug Application and Grants Priority Review for TLX101-CDx (Pixclara®) Brain Cancer Imaging Agent
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Telix Spins Off Rhine Pharma™ to Expand Global Access to Radiopharmaceuticals
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Telix Files Form 20-F Registration Statement for Nasdaq ADS
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Telix Q3 2024 Business Update – Quarterly Revenue Exceeds AU$200M
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
First Patient Dosed in Phase II ‘CA-NINE’ Trial of TLX250-CDx for Detection of Recurrent Kidney Cancer After Surgery
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Telix to Acquire RLS to Expand North American Manufacturing and Distribution Platform
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Telix Announces Cardinal Health as U.S. Commercial Distributor for Zircaix®
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX CAH
‘Highly Accurate’: Telix’s Phase III ZIRCON Trial for Kidney Cancer Imaging Published in The Lancet Oncology
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
IPAX-1 Study of TLX101 Investigational Glioblastoma Therapy Published in Neuro-Oncology Advances
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Telix Submits NDA for TLX101-CDx (Pixclara™) Brain Cancer Imaging Agent
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Telix Announces Reorganisation to Deliver on Strategic Priorities
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Telix 2024 Half-Year Results: Strong Commercial Revenue and Profit Growth to Support Strategic Priorities
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Expanded Access Program Opens in the U.S. for TLX101-CDx, Telix’s Investigational Glioma (Brain Cancer) Imaging Agent
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
FDA Accepts Telix NDA for New Prostate Cancer Imaging Agent
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Q2 2024 Revenue and Business Highlights, Guidance Upgrade
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Telix Welcomes CMS Proposal to Improve Payment for Specialised Diagnostic Radiopharmaceuticals
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Telix Announces Launch of Proposed Initial Public Offering in the United States
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Telix Completes TLX250-CDx (Zircaix™) BLA Submission for Kidney Cancer Imaging
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Telix Announces Positive rPFS Data from ProstACT SELECT Trial of TLX591 rADC Therapy Candidate in Prostate Cancer
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Telix Submits NDA for New Prostate Cancer Imaging Agent
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Telix Completes Proof-of-Concept Study of TLX592 Targeted Alpha Therapy in Prostate Cancer
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Telix Files Registration Statement for Proposed Initial Public Offering in the United States
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Q1 2024 Revenue and Business Update
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
TLX101-CDx (Pixclara™) Granted FDA Fast Track Designation
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
QDOSE® Platform Partnership for Personalized Dosimetry in Radiopharmaceutical Therapy
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Appointment of Dr Darren Patti to Group Chief Operating Officer
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Telix to Acquire ARTMS, Inc. and its Advanced Isotope Production Platform
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Telix Expands U.S. Development and Manufacturing Infrastructure with Acquisition of IsoTherapeutics
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
Telix 2023 Full Year Results: Inaugural Profit Achieved, Strong Revenue Growth Underpins Investment in Late-stage Pipeline
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.